SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EVRAN SEDAT
(Last) (First) (Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
(Street)
HERCULES CA 94547
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIOB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Global Supply Chain
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Bio-Rad A Common Stock 10/20/2024 M 1,044(1) A $0 1,188.14(2) D
Bio-Rad A Common Stock 10/20/2024 F 335 D $346.37 853.14 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(3) 10/20/2024 M 1,044 (4) (4) Bio-Rad A Common Stock 1,044 $0 3,132 D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Includes 49.0480, 41.3870 and 33.7050 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/31/2023, 03/31/2024 and 06/30/2024, respectively.
3. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
4. On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
/s/ Sedat Evran 10/22/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Bio Rad Laboratories Charts.
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Bio Rad Laboratories Charts.